# Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

> **NCT05253833** · PHASE2 · COMPLETED · sponsor: **Arthrosi Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- Gout
- Arthritis, Gouty
- Hyperuricemia
- Gout Chronic

## Interventions

- **DRUG:** AR882 Dose 1
- **DRUG:** AR882 Dose 2
- **DRUG:** Allopurinol Tablet

## Key facts

- **NCT ID:** NCT05253833
- **Lead sponsor:** Arthrosi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-12
- **Primary completion:** 2024-08-13
- **Final completion:** 2024-10-28
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253833, "Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05253833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*